ChiCTR2100049504 版本V1.0 版本创建时间2022/03/03 21:35:02 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100049504 

最近更新日期:

Date of Last Refreshed on:

2021-08-02 12:48:23 

注册时间:

Date of Registration:

2021-08-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

9例MSI-H肺癌患者的回顾性描述性分析

Public title:

Retrospective descriptive analysis of 9 patients with MSI-H lung cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

9例MSI-H肺癌患者的回顾性描述性分析

Scientific title:

Retrospective descriptive analysis of 9 patients with MSI-H lung cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曹国强 

研究负责人:

李力 

Applicant:

曹国强 

Study leader:

李力 

申请注册联系人电话:

Applicant telephone:

023-68757780

研究负责人电话:

Study leader's
telephone:

023-68757780

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cgq1963@163.com

研究负责人电子邮件:

Study leader's E-mail:

lili10119@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区长江支路10号

研究负责人通讯地址:

重庆市渝中区长江支路10号

Applicant address:

10 Changjiang Branch Road,Yuzhong District,Chongqing,China

Study leader's address:

10 Changjiang Branch Road,Yuzhong District,Chongqing,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

408000

申请人所在单位:

陆军军医大学大坪医院

Applicant's institution:

Daping Hospital,Army Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

202172

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军陆军特色医学中心伦理委员会

Name of the ethic committee:

Ethics Committee of Daping Hospital,Army Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-05-26 00:00:00

伦理委员会联系人:

曹国强

Contact Name of the ethic committee:

曹国强

伦理委员会联系地址:

重庆市渝中区大坪长江支路10号

Contact Address of the ethic committee:

10 Changjiang Branch Road,Yuzhong District,Chongqing,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

陆军军医大学大坪医院

Primary sponsor:

Daping Hospital,Army Medical University

研究实施负责(组长)单位地址:

重庆市渝中区大坪长江支路10号

Primary sponsor's address:

10 Changjiang Branch Road,Yuzhong District,Chongqing,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

陆军军医大学大坪医院

具体地址:

渝中区长江支路10号

Institution
hospital:

Daping Hospital,Army Medical University

Address:

10 Changjiang Branch Road, Yuzhong District

经费或物资来源:

Source(s) of funding:

No

研究疾病:

非小细胞肺癌  

Target disease:

non-small cell lung cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

病例研究 

Study design:

Case study 

研究目的:

旨在为填补关于MSI-H肺癌患者的空白为今后医务工作者治疗MSI-H肺癌患者提供一定指导性方向并为MSI-H肺癌患者的治疗带来福音  

Objectives of Study:

The purpose of this study is to fill the gap of MSI-H lung cancer patients, provide guidance for medical workers in the treatment of MSI-H lung cancer patients in the future, and bring good news for the treatment of MSI-H lung cancer patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①收集2018年1月—2021年1月病理诊断为非小细胞肺癌,包括局部晚期、转移性、术后复发或化疗后疗效不佳的患者;②基因检测:MSI-H;

Inclusion criteria

① From January 2018 to January 2021, patients with pathologically diagnosed non-small cell lung cancer, including locally advanced, metastatic, postoperative recurrence or poor efficacy after chemotherapy, were collected; ② Gene detection: MSI-H;

排除标准:

①合并感染;②治疗信息不详;③患者依从性差;④未成年患者,妊娠期或者哺乳期患者;

Exclusion criteria:

① Co infection; ② Treatment information was not available; ③ Patients' compliance was poor; ④ Minor patients, pregnant or lactating patients;

研究实施时间:

Study execute time:

From 2021-07-22 00:00:00 To 2021-08-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-07-22 00:00:00 To 2021-08-30 00:00:00

干预措施:

Interventions:

组别:

连续入组

样本量:

9

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

陆军军医大学大坪医院 

单位级别:

三级甲等 

Institution
hospital:

Daping Hospital, Army Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疗效

指标类型:

主要指标

Outcome:

Therapeutic Evaluation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 58 years
最大 Max age 78 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-08-02 12:48:23